Evusheld™ prescribing in primary care

July 2022

Professor Michael Dooley
Director of Pharmacy, Alfred Health

VICTORIA State Government | Department of Health

Tixagevimab and cilgavimab (Evusheld™) overview

- Provisional approval from TGA for **pre-exposure prophylaxis**
- Monoclonal antibodies designed to block viral attachment and entry into cells
- Available through the NMS and utilised in health services since April 2022
- Treatment goal is to prevent COVID-19 infection in people who:
  - are moderately-severely immunocompromise or,
  - can not be vaccinated due to severe allergy
- Eligibility criteria in Victoria further defined to manage supply availability

Evusheld™ eligibility - Victoria

- Heart/lung transplant recipients
- STEM cell transplant, CAR T-cell therapy recipients, kidney, pancreas/islet cell or liver transplant recipients within 12 months
- STEM cell transplant with GVHD or requiring significant ongoing immunosuppression for other reasons
- Kidney, pancreas/islet cell or liver transplant recipients requiring therapy for acute rejection or significant ongoing immunosuppression for other reasons
- Primary immunodeficiency syndromes
- Haematologic disorders that may affect B cell function eg. CLL, CMML, myelodysplastic syndrome, myeloma
- Unable to be immunised due to genuine, severe allergy if ≥ 65 years old (≥ 50 years old if Aboriginal) and not recently infected with COVID-19 within 3 months
- Haematological malignancies and are receiving active therapy
- HIV with a CD4 cell count < 50 cells/mm3
- Received B and T cell depleting therapies last 12 months

Evusheld™ prescribing considerations

Administration

- 2x IM sequential injections (1.5mL tixagevimab and 1.5mL cilgavimab)
- Observe for 15 minutes post

Contraindications

- COVID-19 infection within the last 30 days
- COVID-19 vaccination within the last 2 weeks
- Weighs < 40 kg
- Age < 12 years old
- Hypersensitivity to active ingredients or other components of the product

Evusheld™ prescribing considerations

Precautions

- Breastfeeding or pregnancy (category B2)
- Clinically significant bleeding disorders, such as thrombocytopenia and other coagulation disorders
- Aged 12-17 years old
- Cardiovascular history

Evidence

- PROVENT trial reduced the risk of developing symptomatic COVID-19 by 83% at 6 months

Evusheld™ primary care pathway

- The department will soon stock doses of Evusheld™ in **selected** community (Supercare) and regional and rural hospital pharmacies
- GPs will be able to prescribe Evusheld™ for eligible patients
- Patients will be dispensed Evusheld™ for free at participating pharmacies
- Option for administration at Supercare pharmacies by onsite nurses (6-10pm) or patients return to prescriber's clinic for administration
- Requires **prescription** and completed **Request to Access form**

TO BE COMPLETED BY PRESCRIBER:

PATIENT DETAILS

Patient Initials _____ Patient DOB (dd/mm/yyyy) _____

Sex

☐ Male ☐ Non-binary ☐ Other
☐ Female ☐ Not disclosed

Planned location of administration _____

DOSE AND ROUTE

300mg (150mg of both tixagevimab plus cilgavimab) ☐ IM (2 X 1.5ml inj)

ACCESS CRITERIA (tick each criterion that applies to confirm the access criteria have been met)

☐ Stem Cell Transplant or CAR T- cell therapy within 12 months

☐ Stem Cell recipient with GVHD, OR still requiring significant ongoing immunosuppression for other reasons

☐ Heart/lung transplant

☐ Kidney, pancreas/islet cells or liver transplant recipients within 12 months

☐ Kidney, pancreas/islet cells or liver transplant recipients requiring therapy for acute rejection, OR still requiring significant ongoing suppression for other reasons

☐ Primary immunodeficiency syndromes. Please specify _____

☐ B or T cell depleting therapy within the previous 12 months. Please specify _____

☐ Haematological malignancy on active therapy

☐ Haematologic disorders that may affect B cell function e.g. CLL, CMML, myelodysplastic syndrome, myeloma

☐ Individuals unable to be immunised with COVID-19 vaccines due to genuine, severe allergy if ≥ 65 years old (≥ 50 years old if Aboriginal) and not recently infected with COVID-19 within 3 months

☐ Individuals with HIV who have a CD4 cell count < 50 cells/mm^3

PRESCRIBER DETAILS

Prescriber Full Name _____ Prescriber Email _____

Prescriber Job Title _____ Phone Number _____

☐ I declare that the above information is accurate at the time of completion and agree to provide patient outcome information when requested by the Victorian Department of Health.

☐ I declare that patient consent for treatment with Evusheld™ has been obtained.

Evusheld™ resources to support prescribing

- Evusheld™ community prescriber guide
- Evusheld™ FAQ for clinicians
- Evusheld™ patient fact sheet
- Dedicated community prescriber website with all of the above resources and locations of selected pharmacies
- Pharmacy helpline
- Consumer web content and comms to support awareness also in train

Victorian COVID Therapies PBS Prescriber Helpline

- Pharmacy helpline launched 18 May to support GPs in the prescription of oral antivirals
- **Can also be used for Evusheld™ enquiries**
- Staffed by Alfred Health pharmacists experienced in prescribing COVID-19 medicines
- 7 days a week 8am-5pm
- (03) 8290 3801

Further information

Department:

COVID-19 medications resources

covid+pathways@health.vic.gov.au

Other:

Australian guidelines for the clinical care of people with COVID-19

TGA product information